Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-ascending-dose placebo-controlled study of Lu AF09535 in healthy men with food-effect and crossover assessment
NL-OMON37456Phase 1Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lu AF09535 in Fragile X syndrome (FXS) (3 arms), sponsored by Lundbeck. Primary endpoint: Safety and tolerability. Started Feb 2012; status: active, not recruiting.
02
Drugs
Lu AF09535
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NL-OMON37456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37456.